title: [EAU guidelines on prostate cancer. Part I: screening, diagnosis, and treatment of clinically localised disease].
abstract: OBJECTIVE
  Our aim was to present a summary of the 2010 version of the European Association of Urology (EAU) guidelines on the screening, diagnosis, and treatment of clinically localised cancer of the prostate (PCa).
  
  
  METHODS
  The working panel performed a literature review of the new data emerging from 2007 to 2010. The guidelines were updated, and level of evidence and grade of recommendation were added to the text based on a systematic review of the literature, which included a search of online databases and bibliographic reviews.
  
  
  RESULTS
  A full version is available at the EAU office or Web site (www.uroweb.org). Current evidence is insufficient to warrant widespread population-based screening by prostate-specific antigen (PSA) for PCa. A systematic prostate biopsy under ultrasound guidance and local anaesthesia is the preferred diagnostic method. Active surveillance represents a viable option in men with low-risk PCa and a long life expectancy. PSA doubling time in < 3 yr or a biopsy progression indicates the need for active intervention. In men with locally advanced PCa in whom local therapy is not mandatory, watchful waiting (WW) is a treatment alternative to androgen-deprivation therapy (ADT) with equivalent oncologic efficacy. Active treatment is mostly recommended for patients with localised disease and a long life expectancy with radical prostatectomy (RP) shown to be superior to WW in a prospective randomised trial. Nerve-sparing RP represents the approach of choice in organ-confined disease; neoadjuvant androgen deprivation demonstrates no improvement of outcome variables. Radiation therapy should be performed with at least 74Gy and 78Gy in low-risk and intermediate/high-risk PCa, respectively. For locally advanced disease, adjuvant ADT for 3 yr results in superior disease-specific and overall survival rates and represents the treatment of choice. Follow-up after local therapy is largely based on PSA, and a disease-specific history with imaging is indicated only when symptoms occur.
  
  
  CONCLUSIONS
  The knowledge in the field of PCa is rapidly changing. These EAU guidelines on PCa summarise the most recent findings and put them into clinical practice.
authors.affiliation: Departamento de Urología, Universidad RWTH Aachen, Alemania. aheidenreich@ukaachen.de
authors.forename: A
authors.initials: A
authors.lastname: Heidenreich
authors.forename: J
authors.initials: J
authors.lastname: Bellmunt
authors.forename: M
authors.initials: M
authors.lastname: Bolla
authors.forename: S
authors.initials: S
authors.lastname: Joniau
authors.forename: M
authors.initials: M
authors.lastname: Mason
authors.forename: V
authors.initials: V
authors.lastname: Matveev
authors.forename: N
authors.initials: N
authors.lastname: Mottet
authors.forename: H P
authors.initials: HP
authors.lastname: Schmid
authors.forename: T
authors.initials: T
authors.lastname: van der Kwast
authors.forename: T
authors.initials: T
authors.lastname: Wiegel
authors.forename: F
authors.initials: F
authors.lastname: Zattoni
mesh_terms: D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D017410:Practice Guidelines as Topic; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000628:therapy*